Share-based Payment Arrangement, Expense of INFINITY PHARMACEUTICALS, INC. from 31 Dec 2013 to 30 Jun 2023
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
- Summary
-
INFINITY PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 30 Jun 2023.
- INFINITY PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2023 was $856,000, a 5% increase year-over-year.
- INFINITY PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2023 was $4,569,000, a 44% increase year-over-year.
- INFINITY PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $3,621,000, a 34% increase from 2021.
- INFINITY PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2021 was $2,695,000, a 85% increase from 2020.
- INFINITY PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2020 was $1,456,000, a 32% decline from 2019.
- Source SEC data
- View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)
INFINITY PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2023 | $4,569,000 | $856,000 | +$41,000 | +5% | 01 Apr 2023 | 30 Jun 2023 | 10-Q | 10 Aug 2023 | 2023 | Q2 |
| Q1 2023 | $4,528,000 | $1,774,000 | +$907,000 | +105% | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 09 May 2023 | 2023 | Q1 |
| Q4 2022 | $3,621,000 | $1,022,000 | +$300,000 | +42% | 01 Oct 2022 | 31 Dec 2022 | 10-K | 28 Mar 2023 | 2022 | FY |
| Q3 2022 | $3,321,000 | $917,000 | +$146,000 | +19% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 14 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $3,175,000 | $815,000 | +$143,000 | +21% | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 10 Aug 2023 | 2023 | Q2 |
| Q1 2022 | $3,032,000 | $867,000 | +$337,000 | +64% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 09 May 2023 | 2023 | Q1 |
| Q4 2021 | $2,695,000 | $722,000 | +$330,000 | +84% | 01 Oct 2021 | 31 Dec 2021 | 10-K | 28 Mar 2023 | 2022 | FY |
| Q3 2021 | $2,365,000 | $771,000 | +$427,000 | +124% | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 14 Nov 2022 | 2022 | Q3 |
| Q2 2021 | $1,938,000 | $672,000 | +$312,000 | +87% | 01 Apr 2021 | 30 Jun 2021 | 10-Q | 09 Aug 2022 | 2022 | Q2 |
| Q1 2021 | $1,626,000 | $530,000 | +$170,000 | +47% | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 03 May 2022 | 2022 | Q1 |
| Q4 2020 | $1,456,000 | $392,000 | -$68,000 | -15% | 01 Oct 2020 | 31 Dec 2020 | 10-K | 29 Mar 2022 | 2021 | FY |
| Q3 2020 | $1,524,000 | $344,000 | -$83,000 | -19% | 01 Jul 2020 | 30 Sep 2020 | 10-Q | 02 Nov 2021 | 2021 | Q3 |
| Q2 2020 | $1,607,000 | $360,000 | -$203,000 | -36% | 01 Apr 2020 | 30 Jun 2020 | 10-Q | 27 Jul 2021 | 2021 | Q2 |
| Q1 2020 | $1,810,000 | $360,000 | -$323,000 | -47% | 01 Jan 2020 | 31 Mar 2020 | 10-Q | 13 May 2021 | 2021 | Q1 |
| Q4 2019 | $2,133,000 | $460,000 | -$404,000 | -47% | 01 Oct 2019 | 31 Dec 2019 | 10-K | 16 Mar 2021 | 2020 | FY |
| Q3 2019 | $2,537,000 | $427,000 | -$429,000 | -50% | 01 Jul 2019 | 30 Sep 2019 | 10-Q | 09 Nov 2020 | 2020 | Q3 |
| Q2 2019 | $2,966,000 | $563,000 | -$282,000 | -33% | 01 Apr 2019 | 30 Jun 2019 | 10-Q | 30 Jul 2020 | 2020 | Q2 |
| Q1 2019 | $3,248,000 | $683,000 | -$200,000 | -23% | 01 Jan 2019 | 31 Mar 2019 | 10-Q | 11 May 2020 | 2020 | Q1 |
| Q4 2018 | $3,448,000 | $864,000 | -$717,000 | -45% | 01 Oct 2018 | 31 Dec 2018 | 10-K | 03 Mar 2020 | 2019 | FY |
| Q3 2018 | $4,165,000 | $856,000 | -$731,000 | -46% | 01 Jul 2018 | 30 Sep 2018 | 10-Q | 30 Oct 2019 | 2019 | Q3 |
| Q2 2018 | $4,896,000 | $845,000 | -$1,152,000 | -58% | 01 Apr 2018 | 30 Jun 2018 | 10-Q | 30 Jul 2019 | 2019 | Q2 |
| Q1 2018 | $6,048,000 | $883,000 | -$924,000 | -51% | 01 Jan 2018 | 31 Mar 2018 | 10-Q | 07 May 2019 | 2019 | Q1 |
| Q4 2017 | $6,972,000 | $1,581,000 | -$1,816,000 | -53% | 01 Oct 2017 | 31 Dec 2017 | 10-K | 14 Mar 2019 | 2018 | FY |
| Q3 2017 | $8,788,000 | $1,587,000 | -$1,202,000 | -43% | 01 Jul 2017 | 30 Sep 2017 | 10-Q | 05 Nov 2018 | 2018 | Q3 |
| Q2 2017 | $9,990,000 | $1,997,000 | -$1,816,000 | -48% | 01 Apr 2017 | 30 Jun 2017 | 10-Q | 07 Aug 2018 | 2018 | Q2 |
| Q1 2017 | $11,806,000 | $1,807,000 | -$1,908,000 | -51% | 01 Jan 2017 | 31 Mar 2017 | 10-Q | 08 May 2018 | 2018 | Q1 |
| Q4 2016 | $13,714,000 | $3,397,000 | -$121,000 | -3.4% | 01 Oct 2016 | 31 Dec 2016 | 10-K | 15 Mar 2018 | 2017 | FY |
| Q3 2016 | $13,835,000 | $2,789,000 | -$1,026,000 | -27% | 01 Jul 2016 | 30 Sep 2016 | 10-Q | 07 Nov 2017 | 2017 | Q3 |
| Q2 2016 | $14,861,000 | $3,813,000 | +$197,000 | +5.4% | 01 Apr 2016 | 30 Jun 2016 | 10-Q | 03 Aug 2017 | 2017 | Q2 |
| Q1 2016 | $14,664,000 | $3,715,000 | -$36,000 | -0.96% | 01 Jan 2016 | 31 Mar 2016 | 10-Q | 09 May 2017 | 2017 | Q1 |
| Q4 2015 | $14,700,000 | $3,518,000 | 01 Oct 2015 | 31 Dec 2015 | 10-K | 15 Mar 2018 | 2017 | FY | ||
| Q3 2015 | $3,815,000 | +$883,000 | +30% | 01 Jul 2015 | 30 Sep 2015 | 10-Q | 09 Nov 2016 | 2016 | Q3 | |
| Q2 2015 | $3,616,000 | +$669,000 | +23% | 01 Apr 2015 | 30 Jun 2015 | 10-Q | 09 Aug 2016 | 2016 | Q2 | |
| Q1 2015 | $3,751,000 | 01 Jan 2015 | 31 Mar 2015 | 10-Q | 04 May 2016 | 2016 | Q1 | |||
| Q3 2014 | $2,932,000 | 01 Jul 2014 | 30 Sep 2014 | 10-Q | 05 Nov 2015 | 2015 | Q3 | |||
| Q2 2014 | $2,947,000 | 01 Apr 2014 | 30 Jun 2014 | 10-Q | 06 Aug 2015 | 2015 | Q2 |
INFINITY PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2022 | $3,621,000 | +$926,000 | +34% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 28 Mar 2023 | 2022 | FY |
| 2021 | $2,695,000 | +$1,239,000 | +85% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 28 Mar 2023 | 2022 | FY |
| 2020 | $1,456,000 | -$677,000 | -32% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 29 Mar 2022 | 2021 | FY |
| 2019 | $2,133,000 | -$1,315,000 | -38% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 16 Mar 2021 | 2020 | FY |
| 2018 | $3,448,000 | -$3,524,000 | -51% | 01 Jan 2018 | 31 Dec 2018 | 10-K | 03 Mar 2020 | 2019 | FY |
| 2017 | $6,972,000 | -$6,742,000 | -49% | 01 Jan 2017 | 31 Dec 2017 | 10-K | 14 Mar 2019 | 2018 | FY |
| 2016 | $13,714,000 | -$986,000 | -6.7% | 01 Jan 2016 | 31 Dec 2016 | 10-K | 15 Mar 2018 | 2017 | FY |
| 2015 | $14,700,000 | +$2,112,000 | +17% | 01 Jan 2015 | 31 Dec 2015 | 10-K | 15 Mar 2018 | 2017 | FY |
| 2014 | $12,588,000 | +$433,000 | +3.6% | 01 Jan 2014 | 31 Dec 2014 | 10-K | 14 Mar 2017 | 2016 | FY |
| 2013 | $12,155,000 | 01 Jan 2013 | 31 Dec 2013 | 10-K | 23 Feb 2016 | 2015 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.